ITP program providing reimbursement for gammaCore ™ extended to March. 31, 2021 with option for additional three years The potential contract value if the three-year extension option is exercised could be up to approximately £3.6 million (or approximately $4.6 million based on the current exchange
ITP program reimbursing for gammaCore™ extended to Sept. 30, 2020 BASKING RIDGE, N.J. , April 08, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that England’s National Health Service ( NHS ) has exercised its option to
ROCKAWAY, N.J. , April 04, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase by clinicians
ROCKAWAY, N.J. , May 24, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase through many of the more than 130 National
ROCKAWAY, N.J. , Jan. 27, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore Sapphire (nVNS) has been included in a new long-term reimbursement policy launched by Matthew Whitty , Director of Innovation
ROCKAWAY, NJ , April 26, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Johns Hopkins University School of Medicine is starting an investigator-initiated trial of non-invasive vagus nerve stimulation (nVNS)
BASKING RIDGE, N.J. , June 21, 2018 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) today announced the pricing of its initial public offering of 5,200,000 shares of common stock at a public offering price of $15.00 per share. All of the shares of common stock are being offered by
ROCKAWAY, N.J. , April 06, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the receipt of a license to import, distribute and market gammaCore Sapphire™, non-invasive vagus nerve stimulator
Reimbursement for gammaCore™ in England BASKING RIDGE, N.J. , Aug. 24, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Official Journal of the European Union (OJEU) has published a Voluntary ex-ante Transparency
Agreement opens reimbursement pathway for thousands of patients with migraine and cluster headache BASKING RIDGE, N.J. , Jan. 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Ascent Health Services on behalf of